NEWS
Print Your Certificate
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
Pradeep Gopalakrishna
Pace University - New York City / United States
Business & Management / Marketing
AD Scientific Index ID: 4994133
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Pradeep Gopalakrishna's MOST POPULAR ARTICLES
1-)
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis CN Harrison, AM Vannucchi, JJ Kiladjian, HK Al-Ali, H Gisslinger, ... Leukemia 30 (8), 1701-1707, 2016 4332016
2-)
The market orientation–performance relationship in the context of a developing economy: An empirical analysis R Subramanian, P Gopalakrishna Journal of Business Research 53 (1), 1-13, 2001 3312001
3-)
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses S Verstovsek, J Gotlib, RA Mesa, AM Vannucchi, JJ Kiladjian, F Cervantes, ... Journal of hematology & oncology 10, 1-6, 2017 2472017
4-)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAM Vannucchi, HM Kantarjian, JJ Kiladjian, J Gotlib, F Cervantes, ...haematologica 100 (9), 1139, 20152672015
5-)
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDM Ross, T Masszi, MT Gómez Casares, A Hellmann, J Stentoft, ...Journal of cancer research and clinical oncology 144, 945-954, 20181542018
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept